



Editorial



Therapeutic Potential of Psilocybin in Alcohol and Opioid Use Disorders: A Promising Role for Psychedelics

Elmira Zolali^{ID}, Lance R. McMahon, Samuel Obeng^{ID}

Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, United States

Received: December 22, 2025, Revised: December 22, 2025, Accepted: December 31, 2025, ePublished: April 30, 2026

Substance use disorder (SUD) remains a major challenge for healthcare systems world-wide. Based on the World Health Organization (WHO)'s most recent data, worldwide deaths related to alcohol consumption in 2019 was 2.6 million, accounting for 4.7% of all deaths, while deaths due to opioid use disorder (OUD) was 448,489 in the same year.¹ According to the Substance Abuse and Mental Health Services Administration (SAMHSA), 17.1% of people in the United States—approximately 48.5 million individuals—had a past-year SUD in 2023. Within this population, 28.9 million had alcohol use disorder (AUD) and 5.7 million had OUD.² There were more than 178,000 deaths from alcohol-related causes from 2020 to 2021 in the United States alone while 79,358 deaths were due to opioid overdose.^{3,4}

Currently, the US Food and Drug Administration (FDA) has approved three medications for OUD: methadone, buprenorphine, and naltrexone.⁵ Methadone has shown better outcomes at higher doses, which increases the risk of overdose.⁶ Buprenorphine requires daily administration, while naltrexone must be administered after supervised medical withdrawal to avoid precipitating acute withdrawal.⁵ FDA approved medications for AUD include disulfiram, acamprosate, and naltrexone. However, adverse effects and poor adherence have limited disulfiram's efficacy. Acamprosate is approved for maintaining abstinence, and its effects are more pronounced when combined with psychotherapy. Naltrexone, while effective in reducing alcohol use, has only modest effects in decreasing relapse rates.⁵ Given the limitations of existing treatments, there is a need to explore novel therapeutic options.

Classic psychedelics are compounds that alter emotions and perception by modulating the 5-hydroxytryptamine (5-HT) system.⁷ Psilocybin is a naturally occurring psychedelic that was identified by Hoffmann from *Psilocybe Mexicana* mushrooms. Psilocybin is a prodrug

which is converted to its active form psilocin by alkaline phosphatase.^{7,8} Psilocybin is considered one of the safest psychedelics and is well tolerated.^{7,8} Psilocin binds to various serotonin receptors, with the highest affinity at the serotonin 2A (5-HT_{2A}) receptor.⁷ Although psilocybin is a Schedule I controlled substance in the US—indicating high abuse potential and no approved medical use—in 2018, the FDA designated psilocybin as a “Breakthrough Therapy” for treatment-resistant depression.⁹ Consequently, clinical research on psilocybin for neuropsychiatric disorders has grown significantly.¹⁰ In a randomized, double-blind trial involving cancer patients, two oral doses of psilocybin administered five weeks apart significantly reduced anxiety and depression, with effects persisting for at least six months.¹¹

Over the past decade, interest in psilocybin for treating SUD has increased. In a proof-of-concept study with 10 volunteers and 36 weeks of follow-up, psilocybin combined with motivational enhancement therapy significantly reduced alcohol craving and increased abstinence.¹² A randomized clinical trial involving 95 participants by Bogenschutz et al. found that psilocybin administration was associated with reductions in both the percentage of heavy drinking days and mean daily alcohol consumption during a 32-week follow-up.¹³ Another study examining psychological changes over 32 weeks in AUD patients showed that psilocybin improved self-awareness, increased self-compassion, and alleviated alcohol cravings and self-critical thoughts.¹⁴ Additionally, psilocybin reduced neuroticism—likely through decreased depression and impulsiveness—and increased extraversion and openness in AUD patients, suggesting normalization of maladaptive personality traits.¹⁵ A recent preclinical study reporting the effect of psilocybin on alcohol self-administration in male rats showed that psilocybin significantly attenuated ethanol intake by downregulating the rewarding effects of alcohol.¹⁶ In a study by Alper et al., they showed that psilocybin has

*Corresponding Author: Samuel Obeng, Email: Samuel.Obeng@ttuhsc.edu

dose- and sex-dependent effects on ethanol consumption. They also showed that a single dose of psilocybin decreased the consumption and preference for ethanol in male animals.¹⁷

The first study investigating the association between classic psychedelic use and opioid misuse was published in 2017.¹⁸ This study analyzed the effects of psychedelics in a large population of opioid users between 2008-2013 and found that psychedelic use was associated with a 27% reduction in past-year opioid dependence and a 40% reduction in past-year opioid abuse.¹⁸ In an online survey conducted by Garcia-Romeu et al individuals with SUDs self-reported a reduction in drug consumption.¹⁹ In a recent preliminary study of two patients with OUD stabilized on buprenorphine therapy, moderate-to-high doses of psilocybin combined with buprenorphine in conjunction with psychedelic-assisted therapy was well tolerated, with no serious adverse effects and minimal withdrawal symptoms or cravings.²⁰ Several ongoing clinical trials are currently evaluating the effects of psilocybin in patients with opioid dependence.²¹⁻²³ Preclinical studies in the OUD field are limited; however, recent studies have shown that psilocybin reduced morphine consumption in mice.²⁴ Furthermore, a study by Floris et al. (2025) investigated the effect of psilocybin on heroin seeking behavior in male rats, and the results indicated that psilocybin effectively inhibited heroin seeking and reduced relapse after forced abstinence.²⁵

Some clinical studies have reported the effect of psilocybin on behavioral effects such as disruption of sleep after drug administration.^{26,27} However, Thomas et al. reported that psilocin slightly suppressed rapid eye movement (REM) sleep in the first hours after consumption in mice, but it did not have significant effects on long-term sleep-awake architecture.²⁸ Also, Fadahunsi et al. revealed that a single dose of psilocybin did not change eating behavior or decrease body weight in binge-like eating behavior and obesity models in animals.²⁹ Further studies are needed to characterize the effect of psilocybin on cognitive and adaptive behaviors.

In conclusion, psilocybin shows promise as a novel and effective therapeutic agent for the treatment of alcohol and opioid use disorders, particularly due to its long-lasting effects. However, it is important to emphasize that these benefits have been observed in conjunction with psychotherapy. Future research should focus on optimizing treatment protocols and conducting large-scale clinical trials to confirm psilocybin's efficacy in SUD populations.

Authors' Contribution

Conceptualization: Elmira Zolali

Supervision: Samuel Obeng, Lance R. McMahon

Writing-original draft: Elmira Zolali

Writing-review & editing: Samuel Obeng, Lance R. McMahon

Ethical Approval

Not applicable.

Funding

No funding was received for this work.

References

1. World Health Organization (WHO). Global status report on alcohol and health and treatment of substance use disorders. 2024. Available from: <https://www.who.int/publications/item/9789240096745>
2. Substance Abuse and Mental Health Services Administration (SAMHSA). 2023 Companion infographic report: Results from the 2021, 2022, and 2023 National Surveys on Drug Use and Health. 2024. Available from: <https://www.samhsa.gov/data/report/2021-2022-2023-nsduh-infographic>
3. National Institute on Alcohol Abuse and Alcoholism (niaaa). Alcohol-related emergencies and deaths in the United States. 2024. Available from: <https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics-z/alcohol-facts-and-statistics/alcohol-related-emergencies-and-deaths-united-states>
4. National Vital Statistics System (nvss). Drug overdose deaths: facts and figures. 2024. Available from: <https://www.cdc.gov/nchs/nvss/drug-overdose-deaths.htm>
5. Volkow ND, Blanco C. Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. *World Psychiatry* 2023;22(2):203-29. doi:10.1002/wps.21073
6. Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the treatment of addiction: methadone. In: Finnegan L, Kandall S, editors. *Women, Children, and Addiction*, 1st ed. Routledge; 2014. p. 88-104.
7. Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, et al. The bright side of psychedelics: latest advances and challenges in neuropharmacology. *Int J Mol Sci* 2023;24(2). doi:10.3390/ijms24021329
8. Hendricks PS, Johnson MW, Griffiths RR. Psilocybin, psychological distress, and suicidality. *J Psychopharmacol* 2015;29(9):1041-3. doi:10.1177/0269881115598338
9. Heal DJ, Smith SL, Belouin SJ, Henningfield JE. Psychedelics: threshold of a therapeutic revolution. *Neuropharmacology* 2023;236:109610. doi:10.1016/j.neuropharm.2023.109610
10. Zhen Z, Sun X, Yuan S, Zhang J. Psychoactive substances for the treatment of neuropsychiatric disorders. *Asian J Psychiatr* 2024;101:104193. doi:10.1016/j.ajp.2024.104193
11. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. *J Psychopharmacol* 2016;30(12):1181-97. doi:10.1177/0269881116675513
12. Bogenschutz MP, Forchimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. *J Psychopharmacol* 2015;29(3):289-99. doi:10.1177/0269881114565144
13. Bogenschutz MP, Ross S, Bhatt S, Baron T, Forchimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. *JAMA Psychiatry* 2022;79(10):953-62. doi:10.1001/jamapsychiatry.2022.2096
14. Agin-Liebes G, Nielson EM, Zingman M, Kim K, Haas A, Owens LT, et al. Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: an interpretive phenomenological analysis. *Psychol Addict Behav* 2024;38(1):101-13. doi:10.1037/adb0000935
15. Pagni BA, Zeifman RJ, Mennenga SE, Carrithers BM, Goldway N, Bhatt S, et al. Multidimensional personality changes following psilocybin-assisted therapy in patients with alcohol use disorder: results from a double-blind, placebo-controlled clinical trial. *Am J Psychiatry* 2025;182(1):114-25.

- doi:10.1176/appi.ajp.20230887
16. Jeanblanc J, Bordy R, Fouquet G, Jeanblanc V, Naassila M. Psilocybin reduces alcohol self-administration via selective left nucleus accumbens activation in rats. *Brain* 2024;147(11):3780-8. doi:10.1093/brain/awae136
 17. Alper K, Cange J, Sah R, Schreiber-Gregory D, Sershen H, Vinod KY. Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice. *Front Pharmacol* 2022;13:1074633. doi:10.3389/fphar.2022.1074633
 18. Pisano VD, Putnam NP, Kramer HM, Franciotti KJ, Halpern JH, Holden SC. The association of psychedelic use and opioid use disorders among illicit users in the United States. *J Psychopharmacol* 2017;31(5):606-13. doi:10.1177/0269881117691453
 19. Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. *Front Psychiatry* 2019;10:955. doi:10.3389/fpsy.2019.00955
 20. Nicholas CR, Horton DM, Malicki J, Baltés A, Hutson PR, Brown RT. Psilocybin for opioid use disorder in two adults stabilized on buprenorphine: a technical report on study modifications and preliminary findings. *Psychedelic Med (New Rochelle)* 2023;1(4):253-61. doi:10.1089/psymed.2023.0012
 21. Louw WF. Standardized natural psilocybin-assisted psychotherapy for tapering of opioid medication. 2023. Available from: <https://clinicaltrials.gov/ct2/show/NCT05585229>
 22. Nayak S. Outpatient buprenorphine induction with psilocybin for opioid use disorder (BIPOD-Out). 2025. Available from: <https://clinicaltrials.gov/study/NCT06067737?term=psilocybin%20opioid&rank=1>
 23. Angarita G. Exploration of synaptotrophic effects of psilocybin in opioid use disorder (OUD). 2025. Available from: <https://clinicaltrials.gov/study/NCT06160284?term=psilocybin%20opioid&rank=5>
 24. Nguyen L, Regonda S, Gaisinsky A. Therapeutic potential of fungally derived psilocybin extract in morphine-dependent Mice: a research protocol. *URNCSST J* 2024;8:1-6. doi:10.26685/urncst.588
 25. Floris G, Dabrowski KR, Zanda MT, Daws SE. Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats. *Mol Psychiatry* 2025;30(5):1801-16. doi:10.1038/s41380-024-02788-y
 26. Froese T, Leenen I, Palenicek T. A role for enhanced functions of sleep in psychedelic therapy? *Adaptive Behavior* 2018;26:129-35. doi:10.1177/1059712318762735
 27. Dudysová D, Janků K, Šmotek M, Saifutdinova E, Kopřivová J, Bušková J, et al. The effects of daytime psilocybin administration on sleep: implications for antidepressant action. *Front Pharmacol* 2020;11:602590. doi:10.3389/fphar.2020.602590
 28. Thomas CW, Blanco-Duque C, Bréant BJ, Goodwin GM, Sharp T, Bannerman DM, et al. Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice. *Transl Psychiatry* 2022;12(1):77. doi:10.1038/s41398-022-01846-9
 29. Fadahunsi N, Lund J, Breum AW, Mathiesen CV, Larsen IB, Knudsen GM, et al. Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. *Transl Psychiatry* 2022;12(1):330. doi:10.1038/s41398-022-02103-9